BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Health > article

SK Bioscience agrees to produce antigen of Novavax COVID-19 vaccine candidate

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : August 14, 2020, 09:14 | Updated : August 14, 2020, 09:14
  • 트위터
  • 페이스북
  • 웨이보
 

[Courtesy of SK Bioscience]


SEOUL -- SK Bioscience, a cooperation partner for South Korea's state project to develop COVID-19 vaccines, will produce the antigen of a vaccine candidate being developed by Novavax, an American vaccine development company, that would be supplied in South Korea and globally if it proves to be safe and effective through clinical trials.

Novavax is undergoing clinical trials for its vaccine candidate, NVX-CoV2373, which was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera in Phase 1 clinical trial. 

In an online ceremony on August 13, the two companies signed a development and supply agreement. SK Bioscience would initiate the production of the NVX-CoV2373 antigen at its vaccine facility in South Korea in August.

"SK Bioscience shares our sense of urgency to ensure broad and equitable access for our COVID-19 vaccine candidate around the world," Novavax CEO Stanley C. Erck said in a joint statement. Novavax has secured $2 billion in funding for its global coronavirus vaccine program, including up to $388 million from the Coalition for Epidemic Preparedness Innovations (CEPI).

The two companies signed a letter of intent with South Korea's Ministry of Health and Welfare to work toward broad and equitable access to NVX-CoV2373 for global use and to make it available in South Korea.

"We will cooperate with the government supporting its two-track strategy, developing vaccine in Korea and securing COVID-19 vaccine from a global manufacturer in a short period of time," said SK Bioscience CEO Ahn Jae-yong. The South Korean company claimed to have secured a candidate for COVID-19 through the protein culture and refining platform of an antigen produced with gene recombination technology.

SK Bioscience would receive $3.6 million from Bill Gates Foundation to find candidate materials for the COVID-19 vaccine. In July, the company signed a contract manufacturing organization (CMO) deal with AstraZeneca PLC, a Swedish-British multinational company. CMO serves other companies in the pharmaceutical industry to provide comprehensive services from development through manufacturing.



 

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .Samsung supports smart production of COVID-19 vaccine syringes.
    Samsung supports smart production of COVID-19 vaccine syring…
  • .S. Korean regulators start review on AstraZeneca vaccine for quick use in February .
    S. Korean regulators start review on AstraZeneca vaccine for…
  • .SK Bioscience embarks on clinical test of COVID-19 vaccine candidate NBP2001 .
    SK Bioscience embarks on clinical test of COVID-19 vaccine c…
  • .[INTERVIEW] Sugentech predicts modest sales after development of vaccines .
    [INTERVIEW] Sugentech predicts modest sales after developmen…
  • .LSK Global PS to conduct third-stage clinical test of Chinese vaccine in Bangladesh.
    LSK Global PS to conduct third-stage clinical test of Chines…

Real Time Photo News

  • .Singer IU drops teaser image for upcoming full album.

    Singer IU drops teaser image for upcoming full album

  • .Cube Entertainment partners with web comics company to create online video content.

    Cube Entertainment partners with web comics company to create online video content

  • .Sci-fi film starring Song Joong-ki to be reelased on Netflix in February.

    Sci-fi film starring Song Joong-ki to be reelased on Netflix in February

  • .Actor Kim Soo-hyun to star in S. Korean remake of British TV drama series Criminal Justice.

    Actor Kim Soo-hyun to star in S. Korean remake of British TV drama series 'Criminal Justice'

  • .CJ ENM partners with NCSoft to roll out new digital content for global market.

    CJ ENM partners with NCSoft to roll out new digital content for global market

Latest News

more+

  • EOFlow to raise new capital for development of wearable artificial pancreas and new businesses
  • En+ Group's metal business partners with Henan Mingtai to deliver low-carbon aluminium products
  • New negative-pressure ambulances to be used by S. Korean fire stations
  • Doosan Mobility's hydrogen drones to be used for safe voyage solutions
  • Samsung supports smart production of COVID-19 vaccine syringes
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view